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Abstract 
 
Alzheimer’s disease (AD) is a fatal neurodegenerative disease which has symptoms related to 
memory loss and cognitive impairment. AD can be categorized as a protein misfolding disease, since 
abnormal accumulation and aggregation of amyloid- (A) peptides in the AD-affected brain are 
associated with neurotoxicity. Moreover, additional pathological features (e.g., metal ion 
dyshomeostasis, oxidative stress) also exist and are indicated to interact with A leading to AD 
pathogenesis. For instance, upon binding of redox-active metal ions with A, facilitation of A 
aggregation, including generation of toxic oligomer species, and production of reactive oxygen 
species (ROS) are observed. The interconnections that affect various microenvironments in cellular 
systems, which in turn cause neuronal death, have hindered the identification of AD etiology. 
Therefore, the determination of an inter-relationship among multiple pathological factors in AD 
pathology would provide a better understanding of AD etiology. The work presented in this 
dissertation focuses on this goal. In Chapter 1, the assembly of A and detailed characterization of A 
oligomers, proposed to be primary toxic species, are introduced. The toxicity mechanisms of A 
oligomers in cellular systems as well as effective inhibitors against A aggregation, including 
oligomerization, are also presented. In Chapter 2, the investigations of the inter-relationship between 
multiple pathological features (e.g., A, metals, metal-bound A, ROS) and a neurotransmitter, 
dopamine, toward AD pathogenesis are described. The direct or indirect regulatory activities of 
dopamine against the pathological features via its oxidative transfigurations are observed, which 
provides advanced information on the role of the neurotransmitter in AD pathogenesis. Finally, in 
Chapter 3, our studies of fluorescent sensors for metal ions in living cells are reported. This work 
might be helpful to further probe metals' pathology in AD. Collectively, our work presented in this 
thesis illustrates a greater understanding and a better insightful view of AD pathology, which could be 
utilized for development of potential therapeutic agents for this disease. 
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Chapter 1. 
Towards an Understanding of Amyloid- Oligomers:  
Characterization, Toxicity Mechanisms, and Inhibitors 
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understanding of Amyloid- Oligomers: Characterization, Toxicity Mechanisms, and Inhibitors, Chem. 
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1.1. Introduction 
Alzheimer’s disease (AD) is a fatal neurodegenerative disorder in the brain.1 One explanation 
regarding AD pathogenesis is the amyloid cascade hypothesis, first put forward by Hardy and 
Higgins, which postulates that amyloid- (A) aggregation and accumulation cause neuronal death 
leading to AD.2 The amyloid cascade hypothesis was challenged by the observation that neuronal 
injury did not necessarily occur where A plaques were deposited.3 This discrepancy, however, was 
reconciled by multiple reports which demonstrated that the neurotoxic effects could instead be 
attributed to soluble and diffusive Aβ oligomers.4 Even in the absence of mature fibers, oligomeric 
species were sufficient to induce toxicity and neuronal death in AD mouse models.5,6  
 Significant efforts have been made to gain a molecular-level understanding of A oligomers’ 
assembly, structural characteristics, and interactions with other biomolecules, such as proteins and 
membranes, to identify how they could trigger toxicity.7-12 Unfortunately, since A oligomers consist 
of a heterogeneous combination of polymorphic intermediates generated by multiple pathways, it has 
been challenging to characterize their structures and properties.7 Despite obstacles, recent progress in 
biophysical and biochemical methods has overcome intrinsic difficulties in investigating A 
oligomers. In addition, the characterization and recognition of specific oligomeric species in the 
extracellular environment and within cellular compartments have suggested mechanisms of Aβ 
oligomers’ toxicity.8,11 Prion-like cell-to-cell transmission of A oligomers might also be one 
mechanism by which A oligomers’ toxicity could spread.13 Moreover, some approaches to modulate 
the formation and presence of A oligomers have been developed to elucidate their roles in amyloid-
related diseases and discover effective diagnostics and therapeutics.14,15 Herein, we review the current 
body of knowledge on the assembly mechanisms and structural properties of A oligomers, as well as 
pathways by which they might induce and transmit toxicity. The remaining part of the review 
describes on some chemical agents (e.g., natural products, synthetic compounds, and peptide/protein 
domains) that can control A aggregation, including oligomers’ formation or disaggregation, towards 
a potential therapeutic avenue.  
 
1.2. Assembly Pathways of A Oligomers 
An amyloid is a type of protein which is susceptible to structural conversion and assembly into cross-
-structured fibrils.1 Amyloid protein aggregation is considered a hallmark in several degenerative 
disorders (e.g., AD, Parkinson’s disease, Huntington’s disease, type II diabetes, and transmissible 
spongiform encephalopathy).1 In the case of AD, it is characterized by multiple pathogenic features, 
one of which is the presence of A plaques in AD patients’ brain tissue.1,2 A peptides are produced 
by proteolytic cleavage of the hydrophobic transmembrane portion of the amyloid precursor protein 
(APP) by - and -secretases (Figure 1.1a).2 They are generated in several isoforms (especially, two 
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A40 and A42 isoforms are the major constituents of amyloid plaques found in AD patients’ brains). 
The difference of only two amino acids between A40 and A42 peptides at their C-terminals results in 
distinct aggregation and toxicity profiles.16,17  
 
 
Figure 1.1. Schematic description of A production and aggregation. (a) A peptides are generated 
by sequential cleavage of APP by - and -secretases. A peptides are natively unfolded; however, 
due to environmental or genetic factors, they can be transformed into partially folded conformations. 
(b) Upon on-pathway oligomerization, A forms structured, transient oligomers which are suspected 
to be toxic. Different types of oligomers, produced via off-pathway fibrillization, are also observed 
and stabilized without further fibril growth. (c) These structured oligomeric species are metastable 
intermediates that are transformed into protofibrils or fibrils. (d and e) Even after the structural 
transition into fibrils, some fibrils can fragment and reassemble into structured oligomeric species 
(fragmentation). In addition, structured oligomers can be generated through interactions between 
monomers and fibrils (secondary nucleation).  
 
 A peptides are natively disordered (that is, they do not have stabilized secondary or tertiary 
structures). Still, they experience conformational fluctuations which can lead to folded or partially 
states.1,7 The presence of external factors (e.g., pH, temperature, peptide concentration, and 
interactions with other molecules) or genetic mutations (e.g., amino acid substitutions) may also 
prompt protein folding.1,7 Partially folded A monomers are prone to interact with one another by 
contacts at their self-recognition sites, which initiates aggregation (Figure 1.1b).1,7 The intermolecular 
interactions between Aβ peptides are sufficient to overcome unfavorable entropical changes; thus, 
amyloid oligomerization is a spontaneous process.1 In the early stages of oligomerization, small 
oligomeric assemblies, suspected to be toxic, generate a nucleus which readily leads to the formation 
of larger aggregates (Figure 1.1b).  
 The polymorphic A species (i.e., species possessing a distinct arrangement of A units into 
diverse three-dimensional structures) that form during the nucleation phase are called on-pathway 
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oligomers and they transform into larger aggregates or -strand fibrils (Figure 1.1b).1,7 On the other 
hand, there are different species which deviate from the principal aggregation/fibrillation pathways 
which are termed off-pathway oligomers (indicated by the green box in Figure 1.1). Off-pathway 
oligomers are distinguishable from on-pathway oligomers, and are generally regarded as unstructured 
and nontoxic.14 Therefore, these amorphous off-pathway species are not recognized by conformational 
antibodies which are specific towards toxic structured oligomers.14 Moreover, off-pathway oligomers 
can be stable final products rather than intermediates,14 in contrast to on-pathway oligomers which are 
transient and transition to protofibrils and fibrils during the elongation phase (Figure 1.1c). 
 Initially, oligomerization and aggregation occur from a pool of Amonomers by a process 
called primary nucleation (Figure 1.1b).18 Another aggregation pathway is directed by heterogeneous 
contacts between monomers and fibrils (secondary nucleation; Figure 1.1e).18 The nucleation phase 
(Figure 1.1b) is considered the rate-limiting step during amyloid fibrillation;1 however, it is 
significantly shortened in secondary nucleation since interactions of monomers with fibrils could 
catalyze oligomerization.18 In addition, although mature fibrils are relatively stable, they can still 
dissociate into small oligomers, due to shear forces, thus contributing to the pool of oligomers 
(fragmentation; Figure 1.1d).18  
One recent study indicated that secondary nucleation and fibril fragmentation are in a positive 
feedback loop.18 This means that fragmentation of fibrillar species raises the amount of oligomeric 
aggregates which seed further aggregation and affect secondary nucleation. Fibril fragmentation of 
mutant-rich domains, such as the Dutch mutant of A, A(16-22)(E22Q), could catalyze a progressive 
assembly pathway through conformational transitions.19 It was shown that secondary nucleation 
overwhelms primary nucleation as a source for new oligomers/aggregates when a critical 
concentration of A fibrils is attained (approximately a few tens of nanomolar concentration).18,19 
Thus, secondary nucleation coupled with fibril fragmentation significantly contributes to the 
proliferation of toxic species,18 in a cascading series of aggregation processes that increase the amount 
of oligomeric and fibrillar A at the expense of nontoxic monomers. The rising level of toxic, 
structured A oligomers exacerbates AD pathology and accelerates neurodegeneration. In light of the 
role structured A oligomers might have in AD pathogenesis, the clarification of their structures and 
toxicity mechanisms has become intensive areas of research as discussed in the next two sections.  
 
1.3. Structural Characterization of A Oligomers 
Although A aggregation has been relatively well documented, the precise nature of toxic agents in 
AD remains unknown. To address this aspect, a structure-toxicity relationship of A oligomers needs 
to be revealed. Numerous characterization studies have currently shed light on the structural 
properties of A oligomers. The difficulties faced by characterization investigations are inherent to the 
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characteristics of A oligomers which are transient and readily convert into other conformations 
during amyloid oligomerization and fibrillation (Figure 1.1).1,7 This results in a heterogeneous 
population of polymorphic, metastable A oligomers; therefore, structural characterization techniques 
that can isolate species from complex mixtures or discern the diverse states from an ensemble are 
necessary.7-12 Recently, in addition to identifying the nature and size of the toxic species and 
intermediate forms, advances in structural characterization methods have provided at the 
topological16,17 and atomic level20-22 structural insight into A oligomers. This section briefly outlines 
the structural and conformational properties of A oligomers and aggregation intermediates at various 
levels of resolution by multiple analytical tactics (Figure 1.2). 
 
 
Figure 1.2. Methods to characterize A oligomers. The isolation and size estimation of A oligomeric 
species can be analyzed by gel electrophoresis, SEC, and single molecule fluorescence spectroscopy. 
A aggregates and fibrils can be visualized by AFM and EM. Three-dimensional oligomeric 
conformations can be reconstructed by SAXS or cryo-EM in conjunction with MD simulations. Some 
probes and antibodies (e.g., BD-Oligo, A11, and KW1) have been adopted to specifically target and 
recognize A oligomers. More detailed structures at the atomic level can be supported by NMR 
spectroscopy and X-ray crystallography. The assembly mechanisms of A oligomers are further 
identified by a combination of IM-MS and MD simulations, along with other methods described 
above. 
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1.3.1 Size Estimation of Toxic A Oligomers 
Although it has been suggested that toxic A species possess specific multiple features, one challenge 
to the elucidation of a structure-toxicity relationship has been ambiguity over which species are 
responsible for toxicity. There have been a number of efforts towards this end to separate, isolate, and 
characterize oligomeric species from metastable heterogeneous mixtures, generally obtained from AD 
brain tissue or cultured AD cells.9-11 The most widely employed techniques to separate and analyze the 
sizes of amyloid oligomers are polyacrylamide gel electrophoresis (PAGE)8-12 and size exclusion 
chromatography (SEC).9-11  
 Ashe and coworkers used PAGE to isolate a 56 kDa A species, probably dodecameric A42 
based on its size in the gel, from brain extracts of 6-month-old AD transgenic mice with memory 
deficits.9 The appearance of this 56 kDa Aspecies in immunoblots of mouse brain tissue coincided 
with onset of memory decline. Introduction of the isolated and purified 56 kDa A directly into the 
lateral ventricle of healthy wild-type rats induced memory loss, assessed by a modified Morris water 
maze, a test of spatial learning and memory dependent on finding an invisible or visible platform that 
allows rats to escape the water. Thus, a causative link between the 56 kDa A oligomeric species and 
memory deficits was affirmed.9  
 Based on separation by PAGE and SEC, Selkoe and coworkers demonstrated that Aβ trimers 
collected from 7PA2 cells expressing mutant human APPV717F could deteriorate long-term potentiation 
(LTP) with greater potency than other oligomers in electrophysiological recordings on mouse 
hippocampal slices perfused with the purified trimers.10 In a similar manner, dimers isolated directly 
from AD patients’ brain samples by SEC had a comparable attenuating impact on LTP, and also 
affected memory when directly implanted into the brain of healthy wild-type rats.11 LTP is a sustained 
increase in the strength of neuronal signals and the decline of LTP is associated with impaired signal 
transduction and deteriorated memory. These studies suggested that soluble diffusible A oligomers as 
causative agents could diminish LTP and trigger some of the symptoms associated with AD.  
 PAGE and SEC are traditional but still widely used techniques. They are limited, however, in 
their ability to determine the exact size and precise distribution of oligomers. Single molecule 
fluorescence spectroscopy has been recently adopted to overcome the limited resolution of PAGE and 
SEC.23 This method infers the number of A monomers compromising an oligomeric assembly by 
counting the number of photobleaching steps of fluorophore-labeled A peptides.23 It is also sensitive 
and can be performed at low concentrations of A closer to physiological levels, hence being more 
relevant to AD pathology. Since it is performed at the single molecule level, it also provides 
information on population heterogeneity rather than on an ensemble measurement. This is an 
important feature in the study of A which adopts such diverse polymorphic states, and in a scenario 
where toxicity may arise from a minor A species.  
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 Recently, small angle X-ray scattering (SAXS) has been adopted to study A oligomers’ 
formation.24 Although SAXS is a lower resolution method, it can examine shorter time scales of A 
aggregation when combined with in-line rapid mixing to derive information on early events. In 
addition, computations from the scattering plot can reveal approximate oligomers’ size (i.e., 
diameter), molecular mass, and extent of polydispersity.24 Ryan and coworkers employed SAXS to 
explore the influence of Cu(II) on A40 and A42 oligomerization in sub- and supra-stoichiometric 
amounts, motivated by the potential role of Cu(II) in AD pathogenesis.7,24 They found that the less 
toxic A40 isoform was formed with elongated protofibril-like structures when Cu(II) was present, 
while A42 with supra-stoichiometric Cu(II) levels developed an ellipsoidal shape of A42 aggregates, 
closer to other reported toxic annular structures.7,12,16,24,25 Thus, SAXS can be used to analyze A 
oligomers’ conformations generated in the early stage of aggregation.  
 
1.3.2 Conformation and Topology of A Oligomeric Species  
Isolation of A oligomers and determination of their size and distribution by PAGE and SEC pointed 
to the likely toxic species. To comprehend how the isolated oligomers could induce toxicity, analysis 
by additional methods is necessary to provide greater structural details with finer resolution because 
the morphologies of A species are not just structural features, but correlated to their toxicity. 
Additionally, since amorphous oligomers generally lacking defined structures are typically regarded 
as nontoxic species,14,26,27 whereas structured oligomers are indicated to be toxic,12,16,17,25 it is 
necessary to reveal the particular structural attributes which trigger toxicity. Therefore, structural 
studies are absolutely critical to the study of A oligomer-mediated pathogenesis, and a variety of 
techniques have been applied towards this goal.  
 The seminal ion mobility mass spectrometry (IM-MS) studies by Bowers et al detected various 
structures for A40 and A42 oligomers, and differences in their preferred configuration.16,17 While 
A42 tetramers preferred a bent structure, they found that A40 tetramers adopted a distinct ring-
shaped configuration. The ring-shaped A40 tetramers had a more enclosed configuration which could 
be less likely to form additional contacts; thus, the A40 tetramers tended to remain small species 
rather than grow into hexamers, dodecamers, or large aggregates.16,17 Bent-shaped A42 tetramers had 
A units at either end of the oligomer capable of forming additional contacts, and the IM-MS studies 
did in fact reveal that they could assemble further into larger donut-shaped dodecamers which had a 
seeding effect and accelerated protofibril elongation.16,17 This study provided insight on the distinct 
toxicity profiles of the two isoforms, and demonstrated how the more toxic A42 could achieve this by 
forming dodecamers known to cause memory deficits.16,17 
 Actual structural topology can be obtained through imaging by atomic force microscopy (AFM) 
and electron microscopy (EM) that have been adopted to probe the morphologies of amyloid 
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oligomers and fibrils at the micrometer and nanometer scale.7,12 An AFM study indicated that amyloid 
proteins, including A peptides, were circularly arranged on lipid bilayers which constituted a 
membrane-permeable pore with a diameter of 8-12 nm.12 The formation of such annular structures 
within cellular membranes could trigger influx into or efflux from cells leading to neuronal death and 
neurodegeneration, which provides an explanation for the toxic nature of structured A oligomers 
compared to amorphous oligomers.12,28  
 Although structural details cannot be fully elucidated solely by AFM and EM, they can be 
complemented with other techniques, such as molecular dynamics (MD) simulations. For example, 
Nussinov and coworkers combined cryo-electron microscopy (cryo-EM) that illustrates three-
dimensional architectural details at few nanometer scale, with MD simulations to reconstruct hollow 
tube assemblies or collapsed non-annular structures of A42 oligomers by matching simulated 
structures to the electron density map from cryo-EM.25 The distinct polymorphs arose from whether 
the A C-terminal faced outward (hollow tube) or inward (non-annular), the relative frequency of 
which was found to be pH dependent.25 Neurotoxicity was associated with the hollow tube 
polymorph, yet it constituted the minor species at physiological pH according to the MD calculations. 
This suggests that toxic A agents may not necessarily be the dominant form, making them critical to 
discern subpopulations of A and emphasizing the complexity involved in full elucidation of all toxic 
forms.  
 
1.3.3 Atomic Details of A Oligomeric Species 
The high-resolution structural analysis of A oligomers has been challenging due to their inherent 
heterogeneity and metastability. One practical strategy to overcome this difficulty is to probe 
kinetically trapped oligomers at specific conditions; therefore, some atomic-scale structures of A 
oligomers have been obtained by 2D NMR spectroscopy20,21 and X-ray crystallography.22 On the basis 
of peak width in 2D NMR, Ishii and coworkers reported that despite the size distribution in spherical 
prefibrillar A40 intermediates, they possessed some structural order with in-register parallel -strand 
structure similar to fibrils. They were able to trap the transient intermediates formed upon incubation 
at 4 °C by freeze-trapping in liquid nitrogen, followed by 2D NMR collection at 15 °C.20 Smith and 
coworkers identified structural properties of A42 pentamers stabilized at a low temperature (ca. 4 °C) 
and low salt concentration (ca. 10 mM).21 These A42 pentamers were disordered, rather than -
stranded, but were relatively more toxic towards neurons than protofibrils or fibrils.21 Nowick and 
coworkers elucidated the crystal structure of oligomers stabilized by incorporating a core A15-23 
segment into macrocyclic -strand peptides.22 Although the macrocyclic peptides were artificially 
designed, their study demonstrated how the amyloid core sequence could generate various assemblies. 
For example, eight A-incorporated cyclic peptides could align into a cruciform octamer which 
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further rearranged into larger oligomers, such as a triangular 24-mer and a hexagonal pore composed 
of three triangular dodecamers.22 Complete atomic-level details on full-length A oligomers at 
physiological conditions are still unavailable; however, the progress made in tackling such a 
challenging area has been remarkable and progresses forward. Such work continues to refine our 
understanding of a structure-toxicity relationship of A oligomers.  
 
1.3.4 Recognition of A Oligomeric Species by Conformation-Specific Probes 
Conformation-specific probes have been developed to recognize and detect the various forms of A. 
Coupled to computational work, by the interaction of the probe with A residues, the arrangement of 
hydrophobic residues relative to the surface of A oligomers can be inferred. More importantly, these 
probes have enabled detection of the extracellular and intracellular localization of structured A 
oligomers in tissues and in cells, which has contributed to our understanding of their toxicity (vide 
infra). An oligomer-specific small molecule fluorescent probe, BoDipy-Oligomer (BD-Oligo), was 
recently reported by Chang and coworkers based on a screen of a library of fluorescent compounds.29 
BD-Oligo was specific towards structured A oligomers through – interactions of its aromatic rings 
with the exposed hydrophobic side chains of A (e.g., F19 and V36) as computational studies 
suggested.29 Injections of BD-Oligo into APP transgenic AD mice demonstrated its low toxicity, 
blood-brain barrier (BBB) permeability, and potential as an in vivo imaging agent showing that it 
could be co-localized with A plaques in brain sections.29  
 In addition to synthetic molecules, there are some antibodies that specifically recognize A 
oligomers, the most widely used of which is A11, first introduced by Glabe and coworkers.30 A11 
recognizes soluble amyloid oligomers (e.g., A, islet amyloid polypeptide (IAPP), and -synuclein 
oligomers) demonstrating the universal conformational properties of toxic structured oligomers.30 
Recently, Fändrich and coworkers reported another oligomer-specific antibody, KW1, which could 
selectively target A oligomers with antiparallel -sheet even in homogenates of AD brain tissue.31 
The selectivity of KW1 originates from interactions with surface-exposed hydrophobic motifs in 
oligomeric species which are buried in fibrils.31 Although it is hard to obtain atomic details of amyloid 
oligomers by using oligomer-specific probes, interactions between A oligomers and these probes 
provide clues to the relative arrangement of hydrophobic or aromatic residues.31 Despite their limited 
use for structural determination, these probes have been invaluable to the elucidation in vivo of A 
oligomers’ location. In addition, the antibodies have found practical applications in biochemical and 
cell molecular techniques, such as Western blot and immunoprecipitation, in the study of mechanisms 
of toxicity of A oligomers. Even with the inherent challenges to elucidating structural details on 
transient, metastable species, progress has been made by collating results from multiple techniques at 
various levels of resolution (Figure 1.2) to assess numerous structural aspects of A, gaining a 
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comprehensive perspective. Equipped with these insights into structural characteristics of A 
oligomers, the monumental but critical task of correlating structures with neurotoxicity is also 
underway, as described in the following section.  
 
1.4. Mechanisms of Toxicity Induced by A Oligomers 
It is becoming increasingly evident that soluble, diffusible A oligomers manifest neurotoxicity in 
AD. Due to the heterogeneous environment and properties in living organisms and of A oligomers 
themselves, the mechanisms by which A oligomers can prompt toxic effects on cellular systems and 
activate neuronal death are complex and challenging to comprehend. In spite of the obstacles, 
investigations with multiple methods have presented greater information about A oligomers’ toxicity 
towards intracellular and extracellular systems, which we discuss in this section on the basis of recent 
findings (Figure 1.3). 
 
Figure 1.3. Proposed mechanisms for toxicity triggered by A oligomers. (a) Interactions of A 
oligomers with lipid rafts in membrane and membrane-bound synaptic receptors can disrupt 
membrane microenvironments. (b) A oligomers can be internalized via association with synaptic 
receptors and accumulate in subcellular compartments, causing damage to organelles and signaling 
pathways. (c) Cell-to-cell transmissible properties of A oligomers could contribute to the 
propagation of neuropathology.  
 
1.4.1. Interactions of A Oligomers with Membranes and Membrane Receptors 
Extracellular A oligomers can affect membranes on multiple levels. They can (i) bind to the 
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membrane causing local perturbations that damage it;28,32,33 (ii) bind to receptors on the membrane 
that influence signal transduction,34,35 induce endocytosis of oligomers into the cell,34,36 or trigger 
damage due to aberrant cellular signaling;35 (iii) form annular structures that insert into the membrane 
leading to unregulated efflux/influx through the created pores (Figure 1.3).28,37 Multiple studies have 
undergone to address these various modes of A oligomers’ toxicity in great detail, too numerous to 
comprehensively review herein. Therefore, we highlight a few on each mechanism in turn, in order to 
illustrate key features of A oligomers’ interactions with cellular membranes. 
Both in vivo and in vitro studies have proposed an interplay between A oligomers and lipid 
rafts which are membrane domains mainly consisting of cholesterol, GM1-ganglioside sphingolipids, 
and synaptic receptors.28,32,33 A dimers were found to accumulate at lipid rafts in the brains of a 
transgenic Tg2576 mouse model which overexpresses Swedish mutant human APP.32 Although the net 
A concentration in vivo is below the threshold that initiates aggregation in vitro, this dense 
accumulation at lipid rafts could raise the local A concentration and thus seed A aggregation and 
plaque formation.32 Another technique, isothermal titration calorimetry adopted by Selkoe and 
coworkers, reaffirmed the observation that A oligomers could interact with lipid membranes more 
rapidly than monomers.33 An immunoprecipitation assay indicated that A dimers were associated 
with GM1-gangliosides in lipid rafts.33 Since lipid rafts are centers of signal transduction, the dense 
collection of A oligomers at those sites could interfere with signal transduction, which could lead to 
memory decline. This possibility is supported by the correlation of A dimers’ accumulation at lipid 
rafts in 6-months old Tg2576 mice with onset of memory impairment.32 Furthermore, fibrillization of 
A oligomers that are concentrated at membranes and lipid rafts can cause membrane fragmentation 
and damage, aggravating A-triggered toxicity.28  
Other factors contributing to cognitive deterioration in AD are the attenuation of LTP, lowered 
synaptic plasticity, and decline of spine density, all of which give rise to synapse loss (Figure 1. 
3a).34,35 Although these neuropathological features of AD have been known for some time, recent 
studies have been bringing mechanistic details to light. They have been revealing that the interaction 
of A oligomers with membrane receptors could be one prominent factor in the initiation of synapse 
loss.34,35 In one study, treatment of human and rat astrocytes with A oligomers increased glutamate 
release as measured by a FRET-based glutamate sensor system (FRET, Förster resonance energy 
transfer), which was not observed following treatment with A monomers.34 Glutamate release was 
found to be calcium dependent, and thus a calcium permeable receptor was sought to mediate this 
effect. It was discovered that glutamate release was initiated by binding of human-derived A trimers 
to astrocytic 7 nicotinic acetylcholine receptors (7 nAChR), a calcium permeable ion channel.34 
The excessive discharge of glutamate overactivated extrasynaptic N-methyl-D-aspartate receptors 
(eNMDARs) on hippocampal neurons decreasing synaptic currents.34  
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In addition to aberrant release of neurotransmitters, complexation of A oligomers with 
receptors (e.g., NMDAR, -amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor, and 
7 nAChR) also promoted internalization of oligomers through endocytic pathways which triggered 
damage to intracellular systems (vide infra).36 The interaction may also alter signaling pathways 
downstream of receptor binding. For example, inappropriate activation of eNMDARs increased 
calcium influx into neurons, initiating the activity of nitric oxide (NO) synthase able to raise the 
concentration of NO, which could lead to apoptosis.34 Elevated NO levels could also lead to enhanced 
nitrosylation of cyclin-dependent kinase 5 (Cdk5), in turn causing S-nitrosylation of dynamin-related 
protein 1 (Drp1), correlated with synaptic spine loss.34 Dendritic spines are small protrusions from 
neuron dendrites that generate synapses with axons from other neurons. Therefore, a loss of spine 
density results in degeneration of neuron synapses and connectivity.  
There are other signaling pathways that affect synaptic spine density. Cellular prion protein 
(PrPc) is abundant in postsynaptic densities and binds to A oligomers.35 Complexes of PrPc with A 
oligomers activate the kinase Fyn which has the dual effect of decreasing NMDAR density at the 
synapse and causing dendritic spine loss.35 Thus, the activation of Fyn exacerbates A oligomers’ 
toxicity since both receptor and spine density are diminished at synapses.  
Along with interactions with membranes and receptors and concomitant aberrant signaling, A 
oligomers can also perforate membranes.28,37 The antiparallel -sheet conformation of A oligomers 
has structural similarities to porin, a -barrel-like bacterial outer-membrane protein.37 Porin can 
disrupt cellular systems by penetrating into membranes, leaving channels large enough to allow 
passive diffusion of smaller-sized molecules thus dysregulating the cellular environment.37 Several 
studies have shown that in a similar manner, pore-shaped structured A oligomers can cause 
membrane leakage by penetrating membranes.12,28,37 This was demonstrated by a dye leakage assay in 
ganglioside-rich large unilamellar vesicles which were used as a model for lipid rafts.28 Dye leakage 
was observed from the vesicles within minutes following treatment with A.28 The leakage could be 
blocked by treatment with Zn(II), indicating that cation-selective channels were formed upon A 
treatment, presumably by the insertion of annular A oligomers into the vesicle membrane.28 Dye 
leakage continued following prolonged exposure to A with onset of fibrillization, except this dye 
leakage was no longer receptive to Zn(II). It indicated that leakage occurred from mechanically 
fragmented membranes, not pores.28 This suggests that early damage to membranes by A is intiated 
by pore formation, and the membrane breaks up mechanically when fibrillization occurs. This damage 
could enhance the uptake of calcium ions, leading to calcium dyshomeostasis, a major aspect of AD 
pathology and dysregulation of which leads to impaired signal transduction and aggravated cellular 
degeneration.12,28,34 When gangliosides were omitted from the vesicles, leakage was much less 
pronounced, confirming other experiments that A oligomers bind to GM1-ganglioside.33 
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Overall, recent studies suggest that A oligomers can induce toxicity by interacting directly 
with cellular membranes and with membrane receptors that activate various signaling pathways. 
Annular A structures can perforate the membrane leading to additional dysregulation of neurons, and 
fibrillization at the membrane can mechanically disrupt it. Further investigation of these mechanisms 
will bring greater clarity on A oligomers’ mechanisms of toxicity which can potentially reveal 
therapeutic targets if the pathways can be blocked. This line of thought has already been tested.34,35 
 
1.4.2 Influence of A Oligomers on Intracellular Processes 
A monomers are secreted into the extracellular space when they are cleaved off from APP.2 This 
extracellular A pool can interact with membranes and receptors, and can also be internalized into 
neurons by endocytic vesicles. Additionally, A can accumulate intracellularly by the production of 
A peptides at organellar membranes where a portion of APP is localized.38-40 Numerous organelles 
are implicated as sites for A generation and aggregation, such as mitochondria, trans-Golgi network, 
endoplasmic reticulum (ER), endosomes, autophagosomes, and lysosomes.38-40 The presence of 
intracellular A oligomers within organelles and at organellar membranes can provoke (Figure 1.3b) 
(i) elevated ER stress, (ii) calcium ion dyshomeostasis, (iii) mitochondrial damage, (iv) altered 
proteolysis, and (v) apoptosis. All these events of cellular damage caused by Aβ oligomers can initiate 
cell death.38-40 
 Mori and coworkers employed APPE693Δ transgenic mice which express a mutant A that 
oligomerizes but does not fibrillize.38 Although this mutation does not affect A production, it can 
increase the level of intracellular A species. Immunohistochemistry of brain sections from APPE693Δ 
transgenic mice demonstrated that A oligomers were co-localized with cellular organelles (i.e., ER, 
endosomes, lysosomes, and mitochondria) in neurons.38 Moreover, compared with wild-type or 
APPwt-transgenic mice, APPE693Δ-transgenic mice exhibited elevated levels of Grp78 (a molecular 
chaperone) and HRD1 (an E3 ubiquitin ligase which tags unfolded molecules for removal and 
destruction). Both are markers indicative of elevated ER stress in APPE693Δ-transgenic mice, which 
was attributed to the intracellular accumulation of A oligomers.38 A oligomers can also trigger ER 
stress through calcium dyshomeostasis.39 In cultured primary cortical neurons, Pereira and coworkers 
suggested that A oligomers induced calcium dyshomeostasis in ER by activation of phospholipase C 
signaling, which can initiate release of calcium from the ER to the cytosol.39 In addition, the A 
oligomer-mediated calcium dyshomeostasis led to decreased cell viability and activation of caspase 3, 
an enzyme that represents the apoptotic pathway.39  
 Oligomeric A can also trigger mitochondrial malfunction,38,40 which is thought to be linked to 
synaptic dysfunction and memory impairment.40 A oligomers abnormally depolarize mitochondrial 
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membranes, releasing cytochrome c, which signals apoptosis when detected in the cytosol.38 
Mitochondrial fragmentation from excessive fission provoked by A oligomers has been considered 
as an additional factor of mitochondrial dysfunction.40 A oligomer-activated S-nitrosylation of 
dynamin-related protein 1 (Drp1), the protein responsible for mitochondrial fission, was proposed by 
Lipton and coworkers as a route to mitochondrial dysfunction.40 Elevated levels of S-nitrosylated 
Drp1 were in fact found in the brains of human AD patients and Tg2576 transgenic mice, validating 
the hypothesis and suggesting that A oligomers could damage the energy producing capabilities of 
neurons leading to further degradation in neuronal function.40 Lastly, proteolysis and intracellular 
signaling are also perturbed by A oligomers.38,41 A oligomers cause lysosomal and endosomal 
membrane leakage, impair proteolysis, and increase efflux of lysosomal enzymes to the cytosol, 
thereby leading to apoptosis.38 Dispersion of lysosome-specific cathepsin D enzyme into the cytosol 
of APPE693Δ-transfected cells implied that lysosomal and endosomal membranes had been ruptured.38 
By damaging endosomal vesicles, A oligomers can interfere with retrograde transport (from synapse 
towards nucleus) of BDNF (brain-derived neurotrophic factor) vesicles, a signaling pathway essential 
to synaptic plasticity and memory.41 A oligomers could downregulate ubiquitin C-terminal hydrolase 
L1, a deubiquitinating enzyme, interfering with proteolysis and possibly resulting in signal 
disruption.41  
 
1.4.3 Transmission of A Oligomers 
The ability of A to seed plaque formation and spread in the brain has been demonstrated in mouse 
and primate models, and has been likened to prion disease.13,42 This transmissible characteristic of A 
has recently been confirmed in human autopsies of patients who had received human cadaver-derived 
growth hormone to treat short stature. Along with the detection of prion CreutzfeldtJakob disease 
(CJD), moderate to severe deposition of A plaques which did not co-localize with prion was also 
observed.13 These patients were aged 36-51 and did not harbor any genetic mutations that were 
commonly associated with early onset familial (inheritable) AD. The suspicion was that AD pathology 
could have arisen from growth hormone preparations that were inadvertently contaminated with A in 
addition to prion, suggesting A-associated pathology may also be transmissible in humans.13 
Although the study did not involve a very large number of autopsies (n = 4), the results merit 
consideration and further study.  
 The spread of A in the brain may occur through a seeding effect of extracellular A in the 
spaces between neurons. It may also occur from intracellular accumulation from endocytosis of A or 
intracellularly processed APP at organellar membranes. Some investigations, however, have suggested 
that A oligomeric seeds could even spread to distant regions via a cell-to-cell transmission 
mechanism (Figure 1.3c).42 Employing a system of donor (contains A) and acceptor (receives A) 
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neurons embedded in a 3D configuration, where the fluorescently labeled A could be tracked from 
donor to acceptor, Nath and coworkers found that several A isoforms transferred (A40, A42, and 
A3pE-40) to varying degrees with A42 expressing the highest level of transmissibility.42 The 
accumulation of A within endosomes and the control of A’s transfer with inhibitors of endosome 
formation suggested that the cell-to-cell transfer of oligomeric A isoforms was mediated by the 
endosomal trafficking system.42 Continuous cell-to-cell propagation of oligomers resulted in large 
lysosomal vesicles which could dysregulate lysosomes in both donor cells and acceptor cells.42 This 
transmissible property of A oligomers could be one molecular mechanism by which A pathology 
may expand in the brain,13,42 but many more studies are required to construct a comprehensive view. 
 
1.5. Inhibitors against A Aggregation  
Since the evidence against A oligomers as toxic agents has mounted, some chemical agents have 
been devised to specifically modulate them or control the aggregation pathways that lead to their 
accumulation.14,15,26,27,43-51 Design approaches for such agents have focused mainly on (i) inhibition of 
A oligomerization;14,43,44 (ii) disaggregation of preformed A oligomers;15 (iii) suppression of toxic 
aggregate formation by redirection of on-pathway aggregates into nontoxic off-pathway 
aggregates;14,26,27,45,46 (iv) disruption of secondary nucleation which otherwise accelerates the growth 
of toxic A oligomers.47  
One method to develop chemical agents for biological applications is to screen chemical 
libraries, composed of known compounds, for potential biological activity.14,15,26,43 Several natural 
products and synthetic molecules that attenuate A oligomer-associated toxicity have been discovered 
in this manner.14,15,26,43 Another approach to expand beyond existing agents and obtain more effective 
chemical tools is to derivatize the molecules found through screening or to newly design and 
synthesize compounds.46,48,49 Recently, rational design of such chemical agents that regulate A 
oligomers and other AD pathogenic aspects (e.g., metals, reactive oxygen species (ROS)) has been 
successful via a (i) linkage48 or (ii) incorporation46,49 approach. In the linkage approach, two or more 
moieties known to interact with A oligomers and/or fibrils are combined together by a chemical 
linker.48 In the incorporation strategy, the structural portions for interactions with A and other 
pathogenic agents are incorporated into the same molecular framework, affording a compact 
molecule.46,49 Moreover, along with small synthetic molecules and natural products, short peptides, 
protein domains, and oligomer-specific antibodies have also been utilized to inhibit the production of 
A oligomers or redirect their aggregation.44,47,50 In this section, we describe the recent progress in the 
development of some chemical agents against A aggregation, including oligomerization, in order to 
diminish their toxicity. 
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Figure 1.4. Selected chemical agents to control A aggregation, including oligomerization. Chemical 
structures of (a) natural products and their derivatives; (b) synthetic molecules; (c) peptide and protein 
domains. 
 
1.5.1. Natural Products and Their Derivatives 
Epidemiological studies have indicated that dietary factors might impact the incidence of AD and 
therefore natural products have garnered interest as possible modulators of A. Various natural 
products have been found to exert a significant influence on A aggregation thereby diminishing the 
toxicity from A oligomers (Figure 1.4a).14,15,26,43,51 Therefore, researchers have directed their efforts 
towards the elucidation of mechanisms by which natural products might redirect A aggregation 
pathways.14,15,26,43,51 Tessier and coworkers categorized natural polyphenols by their ability to 
attenuate A oligomers’ formation via (i) remodeling A oligomers into nontoxic and/or unstructured 
aggregates; (ii) converting oligomers into relatively inert fibrils; or (iii) disassembling structured 
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oligomers into low molecular weight species (i.e. nontoxic monomers).15 Utilizing immunoblotting 
and microscopic methods (i.e., AFM and TEM), they found that naturally occurring polyphenols 
altered A aggregation pathways presumably by interfering with – stacking between aromatic A 
residues and producing covalent adducts with Lys residues in A peptides.15,51 
 One naturally occurring abundant polyphenolic compound found in green tea extracts, ()-
epigallocatechin gallate (EGCG; Figure 1.4a), was shown to inhibit on-pathway A oligomerization 
and fibrillization as well as disaggregate preformed aggregates, which was indicated to promote the 
formation of nontoxic amorphous A oligomers.14,26 Interaction of EGCG with the N-terminal and 
central helical regions of A was revealed by 2D NMR spectroscopy, indicating how EGCG might 
affect A oligomerization.14,26 In addition, EGCG’s reactivity with A was enhanced in the presence 
of metal ions in vitro, which is another benefit since metal ion dyshomeostasis plays a role in AD 
pathogenesis.26 Compaction of A by EGCG in both the absence and presence of metal ions was 
observed by IM-MS with MD simulations, suggesting that EGCG could alter A oligomers’ 
conformations.26 Moreover, EGCG was observed to reduce toxicity triggered by both metal-free and 
metal-associated A in cultured cells.14,26 
Myricetin, curcumin, nordihydroguaiaretic acid (NDGA), rosmarinic acid (RA), and ferulic 
acid (FA) (Figure 1.4a) are natural products that may also be capable of blocking oligomerization.43 
PAGE gels with silver staining showed a dose-dependent inhibitory function of these natural products 
towards A40 and A42 aggregation showing fewer oligomer formation.43 NMR studies indicated that 
NDGA and FA bound to specific amino acid regions of A (e.g., Arg5, Ser8, Gly9, His13, Lys16, 
Asp23, and Ile31) while myricetin caused shifts in the majority of A residues, implying a more 
global conformational change.43 When A40 and A42 were incubated with these natural polyphenols, 
they were stabilized in a random coil state which inhibited conversion to -sheets.43 LTP and long-
term depression (LTD) assays on hippocampal slices presented that synaptotoxic effects induced by 
A oligomers were impeded in the presence of myricetin and RA.43   
Natural products can be utilized to produce new chemical tools that modulate A aggregation 
by rational design and structural modifications.48 For instance, A peptides bind to components in 
lipid rafts (e.g., cholesterol and sphingolipids) and their oligomerization can be prevented by 
polyphenols.48 Zhang and coworkers adopted a rational modification stratagem by taking advantage of 
the ability of two natural products (i.e., cholesterol for binding A and curcumin for inhibiting 
aggregation).48 Following the linkage approach, they conjugated cholesterol with curcumin to design 
bivalent multifunctional A oligomerization inhibitors (BMAOIs; Figure 1.4a).48 The inhibitory 
effect of BMAOI on A oligomerization or aggregation in ML60 cells was dependent on the linker 
length.48 Co-localization of BMAOI with A oligomers and membranes in MC65 cells was observed 
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by immunocytochemistry, confirming that BMAOI could interact with A oligomers as well as be 
localized to membranes and lipids where A oligomers could accumulate.48 BMAOI’s protective 
effect and antioxidant ability were also observed.48 
 
1.5.2 Synthetic Molecules  
Synthetic compounds have been rationally designed to interact with A peptides and modulate their 
aggregation pathways.45,46,49 As an example, a small molecule, L2-b (Figure 1.4b), was observed to 
control metal-bound A complexes (metal–A; e.g., Cu(II)–A and Zn(II)–A) through generation 
and stabilization of A species into unstructured, nontoxic oligomeric species.46,49 L2-b was 
constructed by the incorporation approach in which metal chelation sites (two nitrogen donor atoms) 
were directly installed into the stilbene framework, known to interact with A peptides.46,49 L2-b 
noticeably modulated metal–A aggregation over metal-free A aggregation in vitro as intended by 
the design strategy. IM-MS and NMR studies indicated L2-b’s efficacy in modulating the activity of 
metal–A species via its formation of a ternary complex with metal–A complexes.46,49 Additionally, 
in the case of Cu(II)–A, L2-b could further trigger peptide fragmentation through transient ternary 
complexation with Cu(II)–A.46 In vivo efficacy testing of L2-b in 5xFAD AD mice demonstrated 
that this molecule could diminish the amount of A species in the brain and improved learning and 
memory abilities.46 
Lim and coworkers have recently reported a compact and redox-active molecule, N,N-
dimethyl-p-phenylenediamine (DMPD; Figure 1.4b), which contains moieties (i.e., dimethylamino 
group and one nitrogen donor atom) that potentially interact with metal-free A, metal–A, and metal 
ions.27 DMPD was indeed found to effectively regulate the aggregation of both metal-free and metal-
associated A peptides.27 In contrast to noncovalent aggregation inhibitors, the noticeable activity of 
DMPD towards metal-free A and metal–A was achieved via covalent crosslinking between 
primary amine-containing residues (e.g., Lys16 in A) and the transformed DMPD (i.e., p-
benzoquinone), as confirmed by MS.27 IM-MS presented that the adduct between transformed DMPD 
and A adopted a more compact conformation than compound-untreated A, producing unstructured 
amorphous forms. Additionally, the potential interactions of DMPD with hydrophobic residues in the 
self-recognition and C-terminal regions of A were implicated by a combination of 2D NMR 
spectroscopy and MD simulations.27 Treatment of 5xFAD AD mice with DMPD led to decreased 
loads of toxic amyloid oligomers in the brain with concomitant improvement in cognitive function.27 
Some inhibitory agents exert their effect by generating nontoxic amyloid species via off-
pathway oligomerization rather than by simply decelerating fibrillation kinetics. Synthetic small 
molecules (e.g., L2-b and DMPD) can redirect A peptides into such amorphous nontoxic A 
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oligomers.27,46 In particular, L2-b could produce nontoxic amorphous A oligomers specifically in the 
presence of Cu(II) and Zn(II).46 Therefore, since these small molecules can induce relatively nontoxic 
oligomers, they can lower toxicity linked to A oligomers in cultured cells and/or in vivo.27,46 
 A synthetic molecular tweezers, CLR01 (Figure 1.4b), exhibited reactivity against amyloid 
aggregation by inhibiting oligomerization and fibrillization, and by the disassembly of preformed 
aggregates.45 CLR01 binds specifically to Lys residues by virtue of electrostatic interactions between 
its phosphate groups and the ammonium group of Lys, in addition to hydrophobic interactions 
between the aromatic sides of CLR01 and the lysine butylene moiety.45 Therefore, CLR01 grips Lys 
residues like a pair of tweezers, with an affinity great enough to disrupt unfolded, Lys-containing 
proteins, but not interfere with well-folded, non-amyloidogenic proteins. The premise for the design 
of CLR01 was confirmed by a thioflavin-T (ThT) fluorescence assay (quantification of fibril 
formation) and dot blot assay (immunoblot for the amount of oligomeric A) which exhibited that 
CLR01 inhibited A aggregation, including oligomerization. NMR analysis suggested that CLR01 
could affect amyloid aggregation by interacting with Lys residues of A42 (i.e., Lys16 and Lys28).45 
MD simulations indicated that the intermolecular interactions between two A42 monomers could be 
hindered by CLR01 binding to Lys residues of A42.45 
 
1.5.3 Peptides or Protein Domains 
A small dipeptide, D-tryptophan linked with -aminoisobutyric acid (D-Trp-Aib; Figure 1.4c), was 
prepared to target amyloid oligomers that form in the early stage of A aggregation.44 D-Trp-Aib was 
selected from a library composed of 40 inhibitors to satisfy several criteria: (i) containing a -breaker 
motif that is a moiety capable of disrupting -sheets; (ii) having an “aromatic binder” to interact with 
hydrophobic residues in A; (iii) being metabolically stable D-amino acids for biomedical purposes.44 
In the lead candidate, D-Trp-Aib, the Aib portion is the potent -breaker, while the tryptophan is 
composed of an aromatic indole group for A binding. Additionally, as expected, based on its D-
amino acid constitution, D-Trp-Aib was stable in serum for 24 h, and possessed other attributes 
including low toxicity and some BBB permeability.44 Analyses by gel electrophoresis and EM 
demonstrated that D-Trp-Aib reduced the generation of low molecular weight oligomers in vitro.44 
NMR investigations suggested that the inhibitory activity of D-Trp-Aib against A oligomers could 
be linked to its interactions with the aromatic rings of Phe19 and Phe20, the residues located in the 
self-recognition site of A (Leu17-Ala21).44 Moreover, administration of D-Trp-Aib to AD 
transgenic mice diminished amyloid plaques in brain tissue concomitant with cognitive 
improvement.44 
 Recently, modified antibodies have been adopted to inhibit the formation of amyloid aggregates 
(Figure 1.4c).50 Tessier and coworkers designed Grafted AMyloid-Motif AntiBODIES, abbreviated 
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gammabodies, by fusing either A18-21 (part of the self-recognition motif) or A33-42 (C-terminal) 
peptide fragments to a single domain antibody.50 The resultant gammabodies bound A oligomers 
(grafted A33-42) and fibrils (grafted A18-21 and A33-42) with nanomolar affinity. They could redirect 
A aggregation pathways by forming small gammabody–A complexes and were so potent that they 
could still stabilize A monomers as unstructured conformers even after 6 day incubation.50 This 
inhibitory effect of gammabodies was achieved at sub-stoichiometric concentrations, a feat not 
achieved by conventional antibodies which sequester A in near stoichiometric amounts. Some 
previously reported conformation-specific antibodies were effective at sub-stoichiometric levels, but 
did not achieve it in a manner similar to gammabodies which sequestered A as small nontoxic 
clusters.50  
Another example of protein-based inhibitors is Brichos (Figure 1.4c), an approximately 100 
amino acid domain from the prosurfactant protein C precursor (proSP-C), a member of the Brichos 
family of proteins.47 The Brichos domain of proSP-C possesses chaperone-like activity.47 A series of 
A aggregation experiments were conducted in the absence and presence of Brichos, going to great 
lengths to ensure reproducibility in the aggregation kinetics by careful control of subtle experimental 
parameters. By using modeling to predict the kinetics of fibril formation if Brichos inhibited one of 
three principal steps (i.e. primary nucleation, fibril elongation, and secondary nucleation), they found 
that the best fit between experiment and prediction occurred if Brichos prevented secondary 
nucleation.47 Brichos was able to achieve this remarkable control of secondary nucleation by binding 
directly to A fibrils. Furthermore, the total level of monomers and oligomers was measured with and 
without Brichos presenting that Brichos significantly lowered the amount of toxic oligomers, 
presumably by controlling secondary nucleation, the primary source of oligomers at physiological 
concentrations of fibrils.18,47 Concomitant with the control of toxic A oligomers’ formation, Brichos 
could also reduce signal impairment in A42-treated hippocampal brain slices from C57BL/6 mice.47  
 
1.6. Conclusion 
AD is considered an amyloidogenic disorder characterized by the accumulation and aggregation of 
misfolded A peptides. During aggregation, polymorphic species are generated from A monomers 
yielding a heterogeneous population of transient on-pathway A oligomers that are eventually 
transformed to larger protofibrils and fibrils. The structured A oligomeric intermediates are 
suggested to be the primary toxic agents while fibrils are indicated to be inert and relatively less toxic, 
but can still act as a reservoir of toxic oligomers by fragmentation and secondary nucleation. Recent 
advancements in biochemical and biophysical methods have revealed some structural characteristics 
of A oligomers: (i) isolation and size estimation of oligomeric species have been achieved by PAGE, 
SEC, and single molecule fluorescence spectroscopy; (ii) knowledge of assembly pathways of 
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multiple oligomeric intermediates at the molecular level have been obtained by IM-MS combined 
with MD simulations; (iii) morphological and topological features have been directly visualized by 
AFM, EM, single molecule fluorescence spectroscopy, and SAXS; (iv) atomic details of A 
oligomers have been provided by NMR spectroscopy and X-ray crystallography; (v) recognition and 
targeting of oligomeric species are enabled by conformation-specific probes and antibodies.  
 Along with advances in A oligomers’ characterization, several toxicity mechanisms mediated 
by structured Aβ oligomers have also been proposed. A oligomeric species can exert toxic effects 
through extracellular interactions with membranes or membrane-bound receptors, accumulation at 
intracellular organelles, and cell-to-cell transmission. Until now, a clear relationship between 
oligomers’ structural properties and toxicity has not been fully established; however, the involvement 
of A oligomers in AD pathogenesis has been recognized. This has initiated a search for strategies to 
manage A oligomers to alleviate toxicity. Several natural products, synthetic molecules, and protein 
domains have been discovered or designed to modulate A aggregation as a therapeutic strategy. 
Some inhibitory agents lowered the amount of amyloid oligomers in the brain and improved cognitive 
deficits in animal AD models, suggesting their potential to be utilized for designing new drug 
candidates.  
 Despite the recent progress in elucidating a structure-toxicity relationship of A oligomers and 
the development of inhibitors against A aggregation, multiple important questions remain 
unanswered. The conformations of some A oligomers have been elucidated; however, it is unclear 
whether oligomeric species with different structures have distinct biological roles, and which 
oligomeric state is the most pathologically-relevant form. In addition, it is still obscure how the 
conformations of oligomeric species and their interactions with cellular organelles (e.g., lysosomes, 
mitochondria, and ER) can be correlated with toxicity. Overall, the identification of such fundamental 
aspects will be crucial to gain mechanistic insights into AD pathogenesis as well as advance the 
discovery of novel diagnostics and therapeutics. 
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Chapter 2. 
Oxidative Transformations of Dopamine Determine its Regulatory Activities against 
Pathological Features in Alzheimer’s Disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I thank Jeffrey S. Derrick for performing the studies using TEM, cyclic voltammetry, and 
spectroelectrochemistry and Shin Jung C. Lee for conducting the mass spectrometric experiments. I 
carried out the experiments using gel/Western blot and UV-vis spectroscopy, and analyzed data from 
ESI-MS, IM-MS, and MS/MS.  
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2.1. Introduction 
Dopamine (DA), a neurotransmitter to long-term memory and motor activity in the brain,1 is shown to 
be rapidly oxidized with generation of reactive oxygen species (ROS) even under physiological 
conditions.2-6 Spontaneous oxidation of DA produces its various transfigured forms as shown in 
Scheme 2.1. Formation of dopamine-o-quinone (DQ) causes rapid cyclization affording 
leucoaminochrome (LC), aminochrome (AC), 5,6-dihydroxyindole (HI), and 5,6-indolequinone 
(IQ).2,3 During oxidation processes of DA, HI or IQ can be polymerized to neuromelanin2,3 and ROS, 
such as superoxide anions(O2•−), can be generated.2,4 Since ROS overgeneration is associated with 
oxidative stress, it has been presented that DA’s oxidation could trigger harmful effects potentially 
leading to the pathogenesis of brain diseases.2,3 On the contrary, some perspective has indicated 
protective effects of DA’s oxidation.5,6 For example, one of the products (i.e., neuromelanin) upon  
DA’s oxidation is an antioxidant sequestering redox-active metals.5,6 The link of DA’s oxidation 
particularly to pathological pathways in the brain remains elusive, however.  
 
Scheme 2.1. Proposed oxidative transformations of DA. 
 
 
 
 Various studies have demonstrated the connection of DA with amyloid-related diseases [e.g., 
Alzheimer’s disease (AD), Parkinson’s disease].2,3,7 One of the amyloid-related diseases, AD, is 
characterized by amyloid- (A) peptide aggregation, metal ion dyshomeostasis, and oxidative 
stress.8 DA has been suggested to be correlated with these pathological components via its oxidative 
processes; (i) along with co-localization of A in dopaminergic systems resulting in 
neurodegeneration:9 (ii) prevention of metal-free A aggregation through DA’s oxidation;7 (iii) redox-
active metal-mediated oxidation of DA;2,10 (iv) production of ROS.2,4,11,12 Multiple questions 
regarding the effects of such interactions and reactions of DA with multiple pathological factors found 
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in AD towards the disease pathogenesis are still unclear, however. For instance, the key oxidation 
process of DA, responsible for controlling metal-free A aggregation, has not been fully 
understood.2,3,7 Until now, the interaction of AC (Scheme 2.1) with A has been suggested as an 
active form of preventing A aggregation.7 The covalent adduct formations between DQ (Scheme 
2.1) and amyloid proteins as well as peptide oxidation by DA have been indicated from the studies 
between DA and another amyloid protein (i.e., -synuclein), but not A.2,3,7,13 In addition, the 
influence of DA on modulation of metal-induced A aggregation has not been reported. Moreover, 
controversial results have been presented about DA towards oxidative stress in the brain, since ROS 
could function as signaling factors in biological systems as well as inducers for oxidative stress, 
depending on their concentrations.2,5,6,10-12  
 Herein, we report the regulatory effects of DA towards AD pathological components, such as 
metal-free A, metal-bound A, and ROS through its oxidative transformations. The oxidative 
processes of DA are shown to significantly affect both metal-free A and metal-bound A aggregation 
pathways inducing nontoxic, amorphous off-pathway peptide species. Mass spectrometric (MS) 
studies indicate the oxidation of the amino acid residues of A, such as methionine 35 (Met35), upon 
DA’s oxidation. Such peptide oxidation triggered by ROS generation via DA’s oxidative 
transformations could be a mechanism to modulate A aggregation. In addition, employing a 
chemical library composed of six different structural analogues with different degrees of oxidation, 
produced from variations of DA’s framework, DA’s oxidation is confirmed to be critical for its 
activities with the pathological factors. Taken together, our overall studies demonstrate the 
neuroprotection by DA towards pathological factors found in AD.  
 
2.2. Results and Discussion 
2.2.1. Effects of DA on Modulation of Metal-free A and Metal-induced A Aggregation In Vitro 
In order to investigate the ability of DA to modulate A in the absence and presence of metal ions [i.e., 
Cu(II), Zn(II)], gel electrophoresis with Western blotting (gel/Western blot) and transmission electron 
microscopy (TEM) were carried out to observe the molecular weight (MW) distribution and 
morphological changes of the resultant A species, respectively. Two different of experiments were 
performed using gel/Western blot, as shown in Figures 2.1 and 2.2: (i) Ability of DA to prevent A 
aggregation was tested by inhibition experiments (Figure 2.1) and (ii) its capability of disassembling 
preformed aggregates was examined by disaggregation experiments (Figure 2.2). During the 
incubation, A peptides aggregate and generate large, insoluble aggregates8 that are detected by TEM, 
but too large to penetrate the gel matrix; therefore, only small sizes of A species are observed in the 
gel/Western blot. When A aggregation is inhibited or redirected, various sizes of A species 
permeable through gel matrix can be indicated by smearing a band throughout the lane of gel/Western 
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blot using an anti-A antibody (6E10). In the inhibition experiment, different MW distributions were 
observed for both metal-free A40 and metal-bound A40 species upon treatment with DA. (Figure 
2.1b; top), TEM images of the resultant metal-free A42 and metal-bound A42 aggregates generated 
by addition with DA showed the morphological changes from large fibril-like aggregates to small, 
amorphous aggregates, demonstrating the consistent results with gel/Western blot (Figure 2.1c). On 
the other hand, under anaerobic conditions, the treatment of DA with A results in no discernible 
changes in gel/Western blot compared to DA-untreated metal-free A40 and metalA40 (Figure 2.1b; 
bottom). 
 
 
Figure 2.1. Inhibitory effects of DA on both metal-free and metal-induced A aggregation in the 
presence and absence of O2. (a) Scheme of inhibition experiments. (b) Visualization of the size-
distribution of the resultant A species with and without DA treatment under aerobic (top) and 
anaerobic (bottom) conditions. (c) TEM images of the resultant metal-free A42 and metal–A42 
aggregates from the 24 h incubated samples. The scale bar is 500 nm. Experimental conditions: [A40 
or A42] = 25 M; [ZnCl2 or CuCl2] = 25 M; [DA] = 50 M; pH 6.6 (for Cu(II) samples) or pH 7.4 
(for metal-free and Zn(II) samples); 37 °C; 24 h incubation; constant agitation. 
 
The capacity of DA to dismantle preformed metal-free A and metal-treated A aggregates was 
also revealed by disaggregation experiments (Figure 2.2). After A was preincubated with or without 
metal ions [i.e., Zn(II) or Cu(II)] for aggregation, DA was treated to preformed A aggregates. 
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Similar to the results obtained from inhibition experiments under aerobic conditions, DA had the 
noticeable reactivity toward preformed metal-free and metal-induced A aggregates. Discernible 
smearing bands were observed at all conditions except sample containing the metal-free A42 
aggregates. Overall, our in vitro gel/Western blot and TEM studies suggest that (i) DA could inhibit 
and disassemble both metal-free A and metal-induced A aggregation generating amorphous 
species; (ii) O2 is indicated to play an important role in DA’s controlling reactivity with A peptides.  
 
 
Figure 2.2. Capability of DA to disaggregate preformed metal-free and metal-treated A aggregates. 
(a) Scheme of disaggregation experiments. (b) Visualization of the size-distribution of A40 (left) and 
A42 (right) species with and without DA treatment. Experimental conditions: [A40 or A42] = 25 
M; [ZnCl2 or CuCl2] = 25 M; [DA] = 50 M; pH 6.6 (for Cu(II) samples) or pH 7.4 (for metal-free 
and Zn(II) samples); 37 °C; 24 h incubation; constant agitation. 
 
2.2.2. Oxidation of A by DA 
The reactivity of DA toward both metal-free A and metal-induced A aggregation pathways was 
further probed by electrospray ionization mass spectrometry (ESI-MS) combined with ion mobility-
mass spectrometry (IM-MS) (Figure 2.3). When DA was incubated with metal-free A40, in addition 
to the A404+ monomer peak at 1083.2 m/z, a new peak at 1087.3 m/z (corresponding to the addition of 
an oxygen atom to A404+ monomer) was observed (Figure 2.3a; the peak marked in a red dot). IM-
MS studies of the 4+ charge state presented that the oxidized A40 monomer had the distinct ion 
mobility (IM) time (Figure 2.3b; collisional cross section data in Table 2.1) compared to the A40 
monomer. The oxidized A40 monomer indicated decreased ion mobility (IM) arrival time, suggesting 
its more conformational compaction and role in altering A aggregation pathways, consequently. In 
the presence of Cu(II), oxidation of A40 also occurred after treatment of DA, showing peaks 
corresponding to the addition of one, two and three oxygen atoms to A40 (Figure 2.3c).  
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Figure 2.3. Mass spectrometric analyses of A40 monomers upon treatment with DA. The addition of 
an oxygen atom is marked in a red dot. (a) Mass spectrometric analysis showing A40 oxidation in the 
presence of DA. (b) Arrival time distribution (ATD) of the singly oxidized A404+ peak [A40 + O + 
4H]4+. Collision cross section (CCS) values for all ion mobility data sets are presented in Table 2.1. 
(c) Mass spectrometric analysis of A40 monomers with DA and CuCl2. (d) MS/MS sequencing of the 
oxidized A404+ peak [A40 + O + 4H]4+. Experimental conditions: [A40] = 100 M; [CuCl2] = 100 
M; [compound] = 500 M; pH 7.5; 37 °C; 6 h incubation (for metal-free samples) or 1 h incubation 
(for Cu(II) samples); 100 mM ammonium acetate. Incubated samples were diluted by 10-fold before 
injection into the mass spectrometer. 
 
Table 2.1. Calculated collision cross section (CCS) data from singly oxidized A404+ monomer species  
 
 Conformational Species (Å 2) 
  1 2 3 4 
 
A40 
 
[A40 + 4H]4+ 
 
662.75  
 
727.45  
 
- 
 
- 
      
A40 + DA [A40 + O + 4H]4+ 668.77  692.60  727.44  794.22  
 
To investigate the amino acid residues of A that are oxidized by DA treatment, tandem MS/MS 
in conjunction with collision-induced dissociation (CID) for the singly oxidized A40 was performed 
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to investigate amino acid residues responsible for the A oxidation. Our studies indicated that DA 
could trigger the oxidation of the Met35 residue of A40 (Figure 2.3d). The Met oxidation has been 
linked to the delay of A aggregation pathways14,15 and could generate oligomeric forms different 
from toxic, structured oligomers.16,17 Since the toxicity of A oligomers could be caused by their 
structures,18,19 unstructured, amorphous oligomers are relatively nontoxic.20,21 In addition, retardation 
of amyloidogenic aggregation could prevent the production of oligomers induced by fibril 
fragmentation.22 Thus, the overall aspects have made us consider the nontoxic effects of the Met35-
oxidized A by DA. Upon treatment of A with both Cu(II) and DA, more oxidation to amino acid 
residues of A(not only Met35) was observed. Note that the relative abundance of oxidized A 
species were too low to be further analyzed (the data is not shown). Overall, our ESI-MS, IM-MS, and 
tandem MS/MS studies demonstrate that DA’s regulatory reactivity with aggregation of metal-free 
and metal-bound A is suggested to be resulted from its mediation for A oxidation.  
 
2.2.3. Oxidative Transformations of DA Facilitated by A, Cu(II), and Cu(II)-treated A

 
Figure 2.4. Oxidative transformations of DA. (a) Electrochemical analysis of DA. Cyclic 
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voltammograms of DA in H2O with 1 M NaCl as a supporting electrolyte at variable scan rates (5, 10, 
25, 50, 100, 150, 200, 250, and 300 mV/s). (b) Spectroelectrochemical investigations of DA (0.627 V). 
Potentials were reported and collected versus the Ag/AgCl couple. (c) Transformations of DA with or 
without CuCl2 and/or A40, monitored by UV-vis spectroscopy. Experimental conditions: [A40] = 50 
M; [CuCl2] = 50 M; [compound] = 100 M, pH 6.6 (for Cu(II) samples) or pH 7.4 (for metal-free 
samples); 37 °C; 1 h incubation; no agitation. (d) DA’s transfigurations with or without CuCl2 and/or 
A40 measured by mass spectrometry. Experimental conditions: [A40] = 100 M; [CuCl2] = 100 M; 
[compound] = 500 M; 100 mM ammonium acetate; pH 7.5; 37 °C; 1 h incubation; no agitation. 
Incubated samples were diluted by 10-fold before injection into the mass spectrometer. 
 
To further probe how DA controls the aggregation pathways of metal-free and metal-bound A, 
interactions of DA with A in the absence and presence of metals were analyzed under various 
conditions (Figure 2.4). The redox potential of DA was first investigated by cyclic voltammetry in 
H2O (Figure 2.4a and Table 2.2). The irreversible oxidation wave with the peak anodic potential (Epa) 
at ca. 0.627 V was revealed from DA. To identify optical features upon oxidation of DA, 
spectroelectrochemistry was carried out applying the peak anodic potential obtained from cyclic 
voltammetry. The optical bands at ca. 308 nm and 475 nm, previously assigned to oxidative 
transfiguration of DA to AC,3,23-25 appeared over 60 min incubation followed by generation of black 
precipitates possibly associated with formation of neuromelanin by polymerization of HI or IQ 
(Scheme 2.1) (UV data not shown).3,23 Optical bands corresponding to DQ (i.e., ca. 308 nm and 350 
nm), an intermediate product between DA and AC (Scheme 2.1), were not detected, which may be a 
result of its unstable property and rapid cyclization to AC.2,3,23  
 The optical spectra of DA with or without A40 in the presence or absence of Cu(II) were 
monitored by UV-vis spectroscopy (Figure 2.4c). Upon incubation of DA in a buffer solution, the 
optical bands gradually appeared at ca. 308 nm and 475 nm for 24 h, indicative of the formation of 
AC.3, 22-24 The optical spectrum of DA was stable at ca. 280 nm for 1 h incubation. When DA was 
incubated with Cu(II) or A40, the spectra corresponding to AC were observed within 1 h. Upon 
addition of both A40 and Cu(II), the oxidative transformations of DA were shown to be accelerated. 
The peak matched with the cyclized form of DA was directly indicated within 10 min. After 
identification of the DA’s oxidative transformations in the presence of metal-free A40, Cu(II), and 
Cu(II)-treated A40 by UV-vis spectroscopy, ESI-MS was applied to examine its transformed products. 
This study supported the findings obtained from our UV-vis experiments by detecting peaks 
corresponding to the oxidized products of DA (Figure 2.4d). In a similar manner, DA was incubated 
with or without A40 in the absence or presence of Cu(II) for 1 h. Only a peak at 154 m/z coincided 
with the [DA + H]+ appeared from DA incubated without both A40 and Cu(II). When DA was 
incubated with A40, in addition to the peak assigned to the [DA + H]+, a peak at 150 m/z associated 
with the [AC + H]+ or [HI + H]+ was represented, which could suggest the DA’s cyclization by its 
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oxidation. Upon addition of Cu(II), a generation of the peak at 150 m/z was observed with higher 
relative abundance than the peak from the incubation of DA only with A40. These results could 
explain that the cyclization of DA via its oxidative transformations is linked to its modulating activity 
toward metal-free and Cu(II)-induced A aggregation.  
 
2.2.4. Rational Selection of DA Derivatives  
 
 
Figure 2.5. Derivatives of DA. The catechol moiety (Site I) was systematically altered to 
monomethoxy or dimethoxy functionality. The primary amino group of DA (Site II) was varied with a 
monomethylamino or dimethylamino group.  
 
In order to elucidate DA’s regulatory effects on metal-free and Cu(II)-induced A aggregation via its 
oxidative transformations, structure-reactivity studies were carried out employing our six different 
DA derivatives. These DA derivatives were designed based on the structural modifications of DA 
(Figure 2.5). To identify the importance of DA’s initial oxidation on its reactivity toward metal-free 
and metal-bound A aggregation, a catechol moiety (Site I), critical for the initial oxidation of DA to 
DQ,2,3 was modified to a monomethoxy (1) or dimethoxy group (2). The oxidative transformations 
from DQ to cyclized products (e.g., LC, AC, HI, IQ; Scheme 2.1) occur by a nucleophilic attack of 
the deprotonated side amino group (Site II of DA) to the electron-deficient quinone ring,2,3 thus, the 
role of oxidative cyclization of DA toward modulation of metal-free and Cu(II)-induced A 
aggregation was investigated by substitution of the amino group (Site II) to a methylamino (3) or a 
dimethylamino group (4). Both Site I and Site II were changed to dimethoxy and methylamino groups 
(5) or dimethylamino functionality (6) for comparison of the reactivity with 3 and 4. 
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2.2.5. Reactivity of DA Derivatives with Metal-free and Metal-bound A species 
Redox potentials of DA derivatives. The redox potentials of six derivatives (Figure 2.5) were 
measured and compared with that of DA to analyze DA’s electrochemical behavior by cyclic 
voltammetry (CV). Except for 6, which indicated two quasi-reversible redox couples, only 
compounds equipped with the catechol moiety (i.e., 3 and 4) revealed similar results with DA 
showing irreversible oxidation waves with Epa at ca. 0.657 V and 0.647 V, respectively (Figure 2.6). 
Compounds 1, 2, and 5 were relatively inert toward oxidation compared to DA. No significant anodic 
currents were generated until much more positive potentials were applied (ca. 0.80 V). The peak 
anodic potentials of 1, 2, and 5 were higher than 3, 4, and DA, thus suggesting that the oxidation 
could easily occur from the catechol-included compounds (Figure 2.6). Although 6 with 3,4-
dimethyoxy functionality showed two quasi-reversible redox couples, the peak anodic current (ipa) 
was much lower than that of DA, 3, and 4, suggesting that a relatively small amount of 6 could 
undergo its oxidative transformations compared to the catechol containing DA derivatives. 
Collectively, our electrochemical studies suggest that the catechol functionality is essential for 
significant oxidative transformations of DA. 
 
 
 
Figure 2.6. Cyclic voltammograms of DA’s derivatives in H2O with 1 M NaCl as a supporting 
electrolyte at variable scan rates (5, 10, 25, 50, 100, 150, 200, 250, and 300 mV/s).  
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Table 2.2. Electrochemical parameters obtained from the cyclic voltammograms of DA and its 
derivatives. 
 
 (mV/s) Epa1 (V) Epa2 (v) Epc1 (v) Epc2 (V) ipa1 (A) ipa2 (A) ipc1 (A) ipc2 (A) 
    DA     
5 – 0.555 – 0.238 – 22.01 – -2.26 
10 – 0.563 – 0.231 – 27.90 – -5.63 
25 – 0.580 – 0.217 – 42.28 – -12.92 
50 – 0.601 – 0.206 – 62.34 – -21.14 
100 – 0.609 – 0.196 – 83.34 – -33.06 
150 – 0.611 – 0.187 – 103.12 – -38.83 
200 – 0.619 – 0.184 – 121.01 – -46.66 
250 – 0.620 – 0.179 – 123.67 – -48.23 
300 – 0.627 – 0.176 – 135.62 – -53.86 
    1     
5 0.843 – – – 1.68 – – – 
10 0.867 – – – 2.59 – – – 
25 0.859 – – – 4.92 – – – 
50 0.866 – – – 5.85 – – – 
100 0.877 – – – 9.87 – – – 
150 0.888 – – – 15.21 – – – 
200 0.895 – – – 20.44 – – – 
250 0.896 – – – 27.92 – – – 
300 0.869 – – – 34.02 – – – 
    3     
5 0.565 – 0.232 – 16.04 – -0.64 – 
10 0.574 – 0.214 – 20.93 – -3.09 – 
25 0.587 – 0.200 – 28.09 – -3.93 – 
50 0.599 – 0.191 – 38.38 – -8.94 – 
100 0.614 – 0.180 – 54.34 – -17.09 – 
150 0.623 – 0.171 – 68.25 – -21.80 – 
200 0.632 – 0.167 – 72.40 – -25.10 – 
250 0.638 – 0.160 – 79.34 – -26.83 – 
300 0.657 – 0.160 – 96.19 – -22.63 – 
    4     
5 – 0.640 – 0.353 – 24.00 – -18.42 
10 – 0.638 – 0.353 – 31.13 – -19.62 
25 – 0.618 – 0.344 – 39.67 – -26.41 
50 – 0.597 – 0.333 – 54.09 – -27.95 
100 – 0.605 – 0.227 – 72.76 – -22.24 
150 – 0.611 – 0.215 – 78.45 – -24.30 
200 – 0.615 – 0.201 – 78.37 – -25.36 
250 0.169 0.623 – 0.190  89.54 – -26.87 
300 0.148 0.647 – 0.179  89.87 – -18.96 
    5     
5 0.698 – – – 1.58 – – – 
10 0.729 – – – 2.55 – – – 
25 0.719 – – – 4.89 – – – 
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50 0.704 – – – 6.19 – – – 
100 0.676 – – – 7.48 – – – 
150 0.670 – – – 8.71 – – – 
200 0.676 – – – 8.62 – – – 
250 0.705 – – – 11.5 – – – 
300 0.726 – – – 28.25 – – – 
    6     
5 0.548 0.694 0.487 0.636 3.63 1.62 -2.82 -1.85 
10 0.546 0.697 0.487 0.636 4.81 2.14 -3.72 -3.11 
25 0.544 0.703 0.483 0.632 7.36 3.28 -5.75 -5.02 
50 0.544 0.707 0.480 0.627 9.50 3.77 -6.80 -6.77 
100 0.544 0.719 0.476 0.622 12.92 4.69 -9.00 -8.78 
150 0.545 0.734 0.473 0.620 15.58 5.40 -10.49 -10.45 
200 0.547 0.745 0.471 0.616 17.85 6.31 -11.94 -10.77 
250 0.548 0.758 0.469 0.614 19.92 7.30 -13.59 -10.94 
300 0.554 0.779 0.467 0.612 21.00 9.41 -14.97 -10.03 
 
UV-vis and ESI-MS Studies of DA Derivatives. The oxidative transformations of DA derivatives 
were evaluated and compared with those of DA employing UV-vis spectroscopy as well as ESI-MS. 
Three compounds were selected to compare their structural modifications (i.e., oxidative 
transformations in the presence of A, Cu(II), and Cu(II)-treated A) with those of DA; (i) The 
compounds containing a catechol moiety (i.e., 3 and 4) were selected because of its irreversible 
oxidation waves; (ii) 2, which indicated fully irreversible electron transfer processes, was chosen to 
compare the results with DA, 3, and 4. In UV-vis experiments (Figure 2.7), no significant optical 
changes were observed for DA derivatives in a buffered solution over 60 min (Figure 2.7a). When the 
compounds were incubated with Cu(II) for 60 min (Figure 2.7b), 3, the compound characterized by 
substitution of the amino group in DA’s structure to a methylamino group, indicated similar optical 
bands to those of DA; The growth of new peaks at ca. 308 nm and 475 nm, associated with the 
transition of the chrome form, was observed.24,25 On the other hand, 4 with a dimethyl amino moiety 
indicated a slight spectral shift from ca. 280 nm to 285 nm, presenting no cyclization. Upon 
incubation of these derivatives with A40 in the absence or presence of Cu(II) (Figure 2.7c and 2.7d), 
more distinguishable structural transformations were observed. In particular, the presence of both A40 
and Cu(II) accelerated structural transformations of 3 and 4. In the case of 3, the peaks at ca. 308 nm 
and ca. 475 nm were intensively increased within 10 min. A spectral shift from 280 nm to 308 nm was 
shown from 4, suggesting its transformation to semiquinone form (but not cyclization).24 The addition 
of Cu(II), A40, and Cu(II)-treated A40 slightly increased the absorbance intensity of 2 with 3,4-
dimethoxy and amino groups at ca. 280 nm; however, no spectral changes were further detected. 
３８ 
 
 
 
Figure 2.7. Transformations of 2, 3, and 4 with or without CuCl2 and/or A40, monitored by UV-vis 
spectroscopy. UV-vis spectra of 2, 3, and 4 with or without CuCl2 in the absence (a, b) or presence of 
A40 (c, d) were measured. Experimental conditions: [A40] = 50 M; [CuCl2] = 50 M; [compound] 
= 100 M, pH 6.6 (for Cu(II) samples) or pH 7.4 (for metal-free samples); 37 °C; 1 h incubation; no 
agitation. 
 
Scheme 2.2. Proposed oxidative pathways of DA and its derivatives.  
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 To identify the products from oxidation, the ESI-MS studies were conducted (Figure 2.8). The 
oxidative pathways of 3 and 4 were proposed (Scheme 2.2). Supporting the results obtained from UV-
vis experiments, along with a peak at 168 m/z characterized by [3 + H]+, the incubation of 3 with A40 
and/or Cu(II) generated a 4 Da less new peak at 164 m/z, proposed to be a cyclized product of 3 (e.g., 
3c or 3d). The peaks corresponding to the cyclized form were not indicated from 4; however, a peak 
at 180 m/z coincided with [4a + H]+ was observed by revealing its transition to the quinone form. 
Interestingly, in the presence of Cu(II)-treated A40, the peaks assigned to the transformed products 
were indicated from 3 and 4, implicating their rapid oxidation. Comparing with 3 and 4, the 
incubation of 2 with A40 and Cu(II)-treated A40 only showed a peak matched with [2 + H]+. Overall, 
the importance of a catechol moiety on DA’s reactivity with A, Cu(II), and Cu(II)-bound A is 
reaffirmed. In addition, various oxidative transformations were observed by difference of the amino 
group in DA framework, possibly useful to further investigations to determination of how DA’s 
cyclization process could be associated with its regulatory activity toward metal-free A and metal-
induced A aggregation.  
 
 
Figure 2.8. Transformation of 2, 3, and 4 with or without CuCl2 and/or A40, monitored by mass 
spectrometry. Experimental conditions: [A40] = 100 M; [CuCl2] = 100 M; [compound] = 500 M; 
100 mM ammonium acetate; pH 7.5; 37 °C; 1 h incubation; no agitation. The incubated samples were 
diluted by 10-fold before injection into the mass spectrometer. 
 
Reactivity of DA Derivatives toward Metal-free and Metal-induced A Aggregation. The reactivity 
of DA derivatives toward metal-free and metal-mediated A aggregation was identified. In inhibition 
experiments (Figure 2.9), the compounds, which indicated their redox-active properties and oxidative 
transformations, were able to modulate metal-free and Cu(II)-bound Aaggregation pathways. 
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Discernible smearing bands were not observed when A was incubated with 1, 2, and 5. Although 6 
showed its potential oxidation based on lower ipa, in the CV studies, it did not affect A aggregation. 3, 
the compound showing its cyclized products, modulated the MW of both metal-free A40/42 and 
Cu(II)-bound A40/42 generating amorphous aggregates, observed by TEM. On the other hand, 4, the 
compound showing only quinone products from its oxidative transformation, could control the 
aggregation of Cu(II)-bound A (but not metal-free A FibrillarA42 was identified when A42 was 
incubated with 4 in the absence of Cu(II) (the data is not shown); however, the addition of Cu(II) to 
the 4-treated A42 sample showed smaller and unstructured aggregates.  
 
 
 
 
Figure 2.9. Capacity of DA derivatives to control metal-free and metal-induced A aggregation. (a) 
Scheme of inhibition experiments. (b) Visualization of the size distribution of the resultant A species 
in the absence or presence of DA derivatives (c) TEM images of the resultant metal-free and metal-
induced A aggregates from the 24 h incubated samples. The scale bar is 500 nm. Experimental 
conditions: [A40 or A42] = 25 M; [CuCl2] = 25 M; [compound] = 50 M; pH 6.6 (for Cu(II) 
samples) or pH 7.4 (for metal-free samples); 37 °C; 24 h incubation; constant agitation. 
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Figure 2.10. Mass spectrometric analyses of A40 monomers treated with 3 and 4 in the absence or 
presence of Cu(II). The addition of an oxygen atom is marked in a red dot. Experimental conditions: 
[A40] = 100 M; [CuCl2] = 100 M; [compound] = 500 M; pH 7.5; 37 °C; 6 h incubation (for 
metal-free samples) or 1 h incubation (for Cu(II) samples); 100 mM ammonium acetate. The 
incubated samples were diluted by 10-fold before injection into the mass spectrometer. 
 
 
Figure 2.11. MS/MS sequencing of the oxidized A404+ peak [A40 + O + 4H]4+. Experimental 
conditions: [A40] = 100 M; [compound] = 500 M; pH 7.5; 37 °C; 6 h incubation; 100 mM 
ammonium acetate. The incubated samples were diluted by 10-fold before injection into the mass 
spectrometer. 
 
 ESI-MS studies showed that the reactivities of 3 and 4 toward metal-free and Cu(II)-mediated 
A40 aggregation were also associated with peptide oxidation (Figure 2.10; maked in red dots). A 
incubated with 3 indicated the peaks corresponding to an oxygen atom added to A404+ monomer; 
more oxidation of A was observed in the presence of Cu(II). MS/MS data identified that an oxygen 
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atom was bound to the Met35 residue of metal-free A404+ monomer, which was consistent with the 
studies using DA (Figure 2.11). In addition, the MS data suggested the oxidation of A40 incubated 
with 4 in the presence of Cu(II), which could be analyzed regarding the results obtained from 
gel/Western blot and TEM studies.  
 
2.3. Conclusion 
 DA is suggested to be linked to the pathological components found in AD; however, it is 
unclear how it could interact or react with them at the molecular level. In our present studies, the 
interactions of DA with metal-free A, metals, metal-bound A, and ROS, known to the pathological 
agents in AD, were observed. The different reactivity of DA toward metal-free A and metal-bound 
A under aerobic and anaerobic conditions was indicated. Under our experimental conditions for ESI-
MS, IM-MS, and MS/MS, the reactivity of DA toward metal-free and metal-bound A aggregation 
was linked to A oxidation by DA. In particular, the oxidation of Met35 in A, which could impede 
A aggregation, was presented when DA was incubated with metal-free A. Furthermore, our 
structure-reactivity investigations have presented that the overall oxidative transformations of DA 
would be important for altering metal-free and metal-bound A aggregation pathways. Overall, our 
multidisciplinary investigations demosntrate DA’s mode of action toward multiple pathogenic 
features in AD.  
 
2.4. Experimental Section 
 
Materials and Methods 
All reagents were purchased from commercial suppliers and used as received unless otherwise stated. 
3 was prepared following a previously reported method.26 DA, 1, 2, and 5 were purchased from Sigma 
(St. Louis, MO, USA); 4 and 6 were acquired from Enamine (Monmouth Junction, NJ, USA). Trace 
metal contamination was removed from buﬀers and solutions used for A experiments by treating 
with Chelex (Sigma) overnight. A40 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG 
-VV) and A42 (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were 
purchased from Anaspec (Fremont, CA, USA) and Anygen (Nam-myun, Jangseong-gun, Republic of 
Korea). Double distilled H2O (ddH2O) was obtained from a Milli-Q Direct 16 system (Merck KGaA, 
Darmstadt, Germany). Anaerobic reactions were performed in a N2-ﬁlled glovebox (Korea Kiyon, 
Bucheon-si, Gyeonggi-do, Republic of Korea). Optical spectra were recorded on an Agilent 8453 UV-
vis spectrophotometer. Mass spectrometric analyses were carried out using a Synapt G2-Si quadrupole 
time-of-flight mass spectrometer (Waters, Manchester, UK) or High Capacity Ion Trap (HCT) mass 
spectrometer (Bruker Daltonics, Billerica, MA, USA). Transmission electron microscopy (TEM) 
images were collected on a JEOL JEM-2100 transmission electron microscope (UNIST Central 
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Research Facilities, Ulsan, Republic of Korea).  
 
Electrochemistry  
Cyclic voltammograms were recorded under N2 (g) with a CHI620E model potentiostat (Qrins, Seoul, 
Republic of Korea). A three-electrode setup was utilized, consisting of an Ag/AgCl reference 
electrode (RE-1B Reference electrode (Ag/AgCl); Qrins, Seoul, Republic of Korea), a Pt wire 
auxiliary electrode (SPTE Platinum electrode; Qrins, Seoul, Republic of Korea), and a glassy carbon 
working electrode (Qrins, Seoul, Republic of Korea). Electrochemical analysis of DA and its 
structural derivatives (1 and 3-6; 1 mM) were recorded in H2O with 1 M NaCl as a supporting 
electrolyte at scan rates of 5, 10, 25, 50, 100, 150, 200, 250, and 300 mV/s at room temperature.  
 
Spectroelectrochemistry  
Spectroelectrochemical results for DA was recorded under N2 (g) with a CHI620E model potentiostat 
(Qrins, Seoul, Republic of Korea). Optical spectra were recorded on an Agilent 8453 UV-vis 
spectrophotometer. A spectroelectrochemical cell kit was utilized containing a thin layer quartz glass 
cell, a Pt gauze working electrode, a Pt wire auxiliary electrode (SEC-C Spectroelectrochemical cell 
kit (Pt); Qrins, Seoul, Republic of Korea), and an Ag/AgCl reference electrode (RE-1B Reference 
electrode (Ag/AgCl); Qrins, Seoul, Republic of Korea). Optical spectra of DA were monitored at 
potentials of 0.627 V in H2O with 1 M NaCl as a supporting electrolyte at 37 °C over 60 min.  
 
Amyloid- Preparation 
A peptides were dissolved in ammonium hydroxide (NH4OH, 1% v/v, aq), aliquoted, lyophilized, 
and stored at −80 °C. A stock solution (ca. 150 M) was prepared by re-dissolving A with NH4OH 
(1% w/v, aq., 10 L) followed by dilution with H2O. The concentration of the solution was 
determined by measuring the absorbance of the solution at 280 nm ( = 1450 M−1cm−1 for A40;  = 
1490 M−1cm−1 for A42).  
 
Transformations of Compounds Detected by UV-vis Spectroscopy  
Optical spectra of DA and its structural analogues (2-4; 100 M) with or without CuCl2 (50 M) in 
the absence or presence of A40 (50 M) were recorded on an Agilent 8453 UV-vis spectrophotometer. 
Chelex-treated buﬀered solutions including HEPES [20 M, pH 6.6 (for Cu(II) samples) or 7.4 (for 
metal-free and Zn(II) samples), and 150 M NaCl] were used for the experiment.  
 
Electrospray Ionization Mass Spectrometry (ESI-MS) and Tandem MS (MS/MS)  
ESI-MS spectra of DA, 3, and 4 were recorded using a Synapt G2-Si quadrupole time-of-flight mass 
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spectrometer (Waters, Manchester, UK) equipped with electrospray ionization source. The spectra of 
2 were obtained using a High Capacity Ion Trap (HCT) mass spectrometer (Bruker Daltonics, 
Billerica, MA, USA). For ESI-MS, the capillary voltage, sampling cone voltage, and source 
temperature were adjusted to 2.8 kV, 70 V, and 40 °C. Tandem MS experiments were conducted for 
the +4-charged singly oxidized A40 with 1087.1 m/z (monoisotopic mass 1086.6 m/z) by setting the 
trap collision energy, LM resolution, and HM resolution as 55 eV, 10, and 15, respectively. All mass 
spectra were obtained under the IMS mode to measure the drift time for each ion. Trap gas flow (Ar), 
helium gas flow, and IMS gas flow (N2) were set as 4 mL/min, 120 mL/min, and 30 mL/min, 
respectively. IMS wave velocity and wave height were adjusted to 450 m/s and 10 V. To investigate 
the transformation of DA and its structural derivatives (2-4), DA and its structural analogues (2-4) 
(500 M) were incubated with or without A40 (100 M) in 100 mM ammonium acetate, pH 7.5, in 
the absence or presence of CuCl2 (100 M). The samples were incubated at 37 °C for 1 h. To further 
probe the influence of DA and its structural derivatives (3 and 4) on A40 aggregation, samples in the 
presence of A40 were prepared following the methods. Metal-free and CuCl2-treated samples were 
incubated at 37 °C for 8 h and 1 h, respectively. The incubated samples were diluted by 10-fold 
before injection into the mass spectrometer.  
 
A Aggregation Experiments 
All experiments were conducted according to previously published methods.19 The peptide stock 
solution was diluted to a ﬁnal concentration of 25 μM in the Chelex-treated buﬀered solution 
containing HEPES [20 μM; pH 7.4 (for metal-free and Zn(II) samples) or pH 6.6 (for Cu(II) samples), 
and NaCl (150 μM)]. For inhibition experiments, A (25 M) was first treated with or without a metal 
chloride salt (CuCl2 or ZnCl2; 25M) for 2 min followed by addition of compounds (50 μM; 1% v/v 
final DMSO concentration). The resulting samples were incubated at 37 °C for 24 h with constant 
agitation. For disaggregation experiments, Aβ in the absence or presence of a metal chloride salt 
(CuCl2 or ZnCl2) was initially incubated at 37 °C for 24 h with constant agitation. The compound was 
added into the resulting solution afterward followed by an additional 24 h of incubation at 37 °C with 
constant agitation. For anaerobic conditions, all samples were prepared in an N2-ﬁlled glovebox. 
 
Gel Electrophoresis with Western Blotting 
The samples from inhibition and disaggregation experiments were analyzed by gel electrophoresis 
with Western blotting (gel/Western blot) using an anti-A antibody (6E10). Each sample (10 L) was 
separated on a 10−20% Tris-tricine gel (Invitrogen, Grand Island, NY, USA). Following separation, 
the proteins were transferred onto nitrocellulose, which was blocked with bovine serum albumin 
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(BSA, 3% w/v, RMBIO, Missoula, MT, USA) in Tris-buﬀered saline (TBS) containing 0.1% Tween-
20 (TBS-T) for 4 h at room temperature. The membranes were incubated with antibody (6E10, 1:2000, 
Covance, Princeton, NJ, USA) in a solution of 2% BSA (w/v in TBS-T) for 4 h at room temperature 
or overnight at 4 °C. After washing, the horseradish peroxidase-conjugated goat anti-mouse secondary 
antibody (1:5000) in 2% BSA was added for 1 h at room temperature. Biosesang ECL Plus kit 
(Biosesang, Gyeonggi-do, Republic of Korea), or a homemade ECL kit was used27 to visualize the 
results on a ChemiDoc MP Imaging System (BioRad, Hercules, CA, USA). 
 
Transmission Electron Microscopy (TEM)  
Samples for TEM were prepared according to previously reported methods.20 Glow-discharged grids 
(Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatﬁeld, PA, USA) were treated with A 
samples from inhibition and disaggregation experiments (5 L) for 2 min at room temperature. Excess 
sample was removed using ﬁlter paper followed by washing three times with H2O. Each grid was 
incubated with uranyl acetate (1% w/v H2O, 5 L, 1 min). Upon removal of excess uranyl acetate 
with ﬁlter paper, the grids were dried for at least 30 min at room temperature before measurement. 
Images from each sample were taken on a JEOL JEM-2100 transmission electron microscope (UNIST 
Central Research Facilities, UNIST, Ulsan, Republic of Korea) at 120 kV and 25000× magniﬁcation. 
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Chapter 3. 
Detection of Metal Ions by Fluorescent Probes in Living Cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results presented in this chapter have been published; (1) Choi, Y. W.; Lee, J. J.; Nam, E.; Lim, M. 
H.; Kim .C., Tetrahedron., 2016, 72, 1998-2005; (2) Lee, J. J.; Kim, Y. S.; Nam, E.; Lee, S. Y.; Lim, 
M. H.; Kim. C., Dalton Trans., 2016, 45, 5700-5712; (3) Jo, T, G. ; Lee, J. J., Nam, E. ; Bok, K. H. ; 
Lim, M. H. ; Kim, C., New J. Chem., 2016, 40, 8918-8927. I conducted imaging experiment to 
monitor fluorescent responses of newly developed sensors to metal ions in living cells.  
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3.1. Introduction 
Metals in the brain (e.g., copper, zinc, iron) are involved in signaling pathways and receptor’s and 
transporters’ functions (e.g., NMDAR, ATP7A);1,2 however, they are strictly regulated since metal ion 
dyshomeostasis, one of the symptoms in AD, could occur the elevation of oxidative stress and 
dysfunction of metalloproteins essential for biological fucntions. Moreover, the accumulation of toxic 
heavy metals, such as mercury, in neuromelanin pigments affects degeneration of neurons.3,4 Multiple 
methods have been developed to visualize actions of metals in the brain. One of the methods applied 
to observe metals’ actions is fluorescence imaging using chemical fluorescent probes in conjunction 
with fluorescence microscopy. Selective and sensitive fluorescent sensors for specific metal ions have 
advanced the visualization of metals’ functions.5 Herein, our studies demonstrate the design of newly 
developed sensor for metal ions and their fluorescent responses to metal ions in living cells.  
 
3.2. Results and Discussion 
3.2.1. Fluorescenct Responses of Compound A to Al(III) in Living Cells 
 
Scheme 3.1. Proposed binding mode of Al(III)A. 
 
 
 
 
Figure 3.1. Fluorescent responses of A to Al (III) in HeLa cells. Cells were exposed to (a) 0 and (b) 
300 μM Al(III) for 4 h prior to addition of A (10 M). Experimental conditions: 37 °C; 5% CO2. The 
scale bar is 100 m. The DAPI light cube [DAPI, 2-(4-Amidinophenyl)-1H-indole-6-carboxamidine; 
excitation 357 (± 22) nm; emission 447 (± 30) nm] was employed to perform imaging experiments.  
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The compound A was developed based on a linkage of julolidine and tryptophan moiety due to 
julolidines’ good applicability in aqueous solution and tryptophan’s fluorescence property, along with 
noncovalent binding forces between metal ions and its indole ring.6,7 The designed and synthesized 
sensor A appeared fluorescent responses in the presence of Al(III). Herein, we report the fluorescent 
response of A to Al(III) in living cells (Figure 3.1). HeLa cells were exposed to A (10 μM) after 
preincubation with Al(III) (300 M) for 4 h. A revealed its fluorescent response to Al(III) at DAPI 
channel [excitation 357 (± 22) nm; emission 447 (± 30) nm], while discernible fluorescence did not 
occur from living cells with either Al(III) or A. Therefore, the potential ability of the new fluorescent 
probe A in biological systems was indicated.  
 
3.2.2. Fluorescent Responses of Compound B to Hg(II) in Living Cells 
 
Scheme 3.2. Fluorescent enhancement mechanism and proposed binding mode of Hg(II) . 
 
 
 
 
 
Figure 3.2. Fluorescent responses of B to Hg(II) in HeLa cells. Cells were pre-incubated with B for 5 
min prior to addition of various concentrations of Hg(II). Experimental conditions: [Hg(II)] = 0, 10, 
20, 30, 40, and 50 M; [B] = 5 M; 37 °C; 5% CO2. The scale bar is 50 m. The GFP light cube 
[excitation 470 (±11) nm; emission 510 (±21) nm] was used to detect the fluorescence. 
 
The sensor, B, for detecting Hg(II), was synthesized and developed based on the photoinduced 
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electron transfer (PET) principle.8 To investigate the fluorescent responses of B to Hg(II) in living 
HeLa cells, imaging experiments were carried out (Figure 3.2). Various concentrations of Hg(II) (i.e., 
0, 10, 20, 30, 40, and 50 M) were treated to the cells before treatment of B. The fluorescent 
responses of B to Hg(II) were observed in a concentration-dependent manner. Any noticeable 
fluorescent response was not observed from the cells incubated with either Hg(II) or B. Thus, these 
results confirmed that B could be a potential chemosensor to detect Hg(II) in biological systems.  
 
3.2.3. Fluorescent Responses of Compound C to Al(III) in Living Cells. 
 
Scheme 3.3. Fluorescent enhancement mechanism and proposed binding mode of Al(III)C. 
 
 
 
 
Figure 3.3. Fluorescent responses of C to Al(III) in HeLa cells. Cells were exposed to (a and b) 0 or 
(c-f) 100 M Al(III) for 1 h prior to addition of C (20 M). (a and c) Bright-field images of cells 
without or with Al(III), respectively. Fluorescent responses to Al(III) were detected in the (b) absence 
or (d) presence of Al(III). To investigate the distribution of fluorescence, (e) the nuclei of cells were 
stained with SYTO16 (2.5 M). (f) Overlapped fluorescence images of (d) and (e). Experimental 
conditions: DAPI channel [ex = 357 (± 22) nm; em = 447 (± 30) nm] for (b) and (d); GFP channel 
[excitation 470 (±11) nm; emission 510 (±21) nm] for (e). The scale bar is 25 m. 
 
The sensor C, for Al(III) in aqueous solution, was developed through the combination of 2-
hydroxybenzaldehyde and oxalohydrazide. To examine the fluorescent responses of C to Al(III) in 
biological systems, imaging experiments were conducted using HeLa cells (Figure 3.3). Fluorescent 
responses of C for Al(III) were only indicated in the presence of Al(III) (Figure 3.3d). To identify the 
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fluorescent localization in the cells, the nuclei were stained with SYTO16 (Figure 3.3e). As shown in 
Figure 3.3f, the overlapped fluorescent image between C with Al(III) and SYTO16, the fluorescent 
dye for the nuclei, suggests that the probe’s fluorescent response to Al(III) occur in the overall parts of 
cells, including nuclei and cytoplasms. Our results suggest the potential use of C as a metal sensor in 
biological systems. 
 
3.3. Conclusion  
Diverse metal ions are vital targets to be detected in order to understand their important roles (e.g., 
signaling, neurotoxicity) in normal and disease-affected brains. Thus, sensitive and selective 
fluorescent sensors have been developed to visualize the localization and actions of metal ions. The 
newly developed sensors, described from our studies, A, B, and C, are shown to indicate their 
fluorescent response to specific metal ions [i.e., Al(III) for A and C, Hg(II) for B] in living cells. In 
the near future, further modifications of these probes should be carried out to improve their properties, 
including biocompatibility and specificity for metal ions. 
 
3.4. Experimental Section 
Imaging Experiments 
HeLa cells were maintained in media containing DMEM, 10% fetal bovine serum (FBS, GIBCO, 
Grand Island, NY, USA), 100 U/mL penicillin (GIBCO), and 100 mg/mL streptomycin (GIBCO). The 
cells were grown in a humidified atmosphere with 5 % CO2 at 37 °C. Cells were seeded onto imaging 
dish (SPL Life Sciences Co., Ltd., South Korea) at a density of 150,000 cells per 1 mL and then 
incubated at 37 °C for 24 h. Cells were treated with various concentration of metal ions (dissolved in 
water) and compounds (dissolved in DMSO; 1% v/v final DMSO concentration; at room temperature). 
Cells were washed with 10 mM bis-Tris buffer (pH 7.4, 150 mM NaCl) twice. Imaging experiments 
were performed with an EVOS FL fluorescence microscope (Life technologies) using a DAPI light 
cube [DAPI, 2-(4-Amidinophenyl)-1H-indole-6-carboxamidine; excitation 357 (± 22) nm; emission 
447 (± 30) nm] or GFP light cube [excitation 470 (± 11) nm; emission 510 (± 21) nm]. 
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